Can anti‑Saccharomyces cerevisiae (ASCA) antibodies be present in patients with diffuse large B‑cell lymphoma (DLBCL)?

ASCA Antibodies in DLBCL

ASCA antibodies are not a recognized feature or diagnostic marker of DLBCL, and there is no evidence linking these antibodies to diffuse large B-cell lymphoma.

Key Points

The provided evidence does not demonstrate any association between ASCA antibodies and DLBCL. Here's what the evidence actually shows:

What ASCA Antibodies Are Associated With

• ASCA antibodies are primarily markers for Crohn's disease, where they help differentiate CD from ulcerative colitis with 57% sensitivity and 87% specificity 1

• ASCA can appear in other autoimmune conditions, including:

  • Systemic lupus erythematosus (31.9% prevalence) 2
  • Antiphospholipid syndrome (20.0% prevalence) 3

Why This Question Arises

The confusion likely stems from the abbreviation "ASCT" (autologous stem cell transplantation) appearing in DLBCL guidelines, which is completely different from "ASCA" (anti-Saccharomyces cerevisiae antibodies):

• ASCT is a treatment modality for relapsed/refractory DLBCL, where allogeneic transplantation may be considered after ASCT failure 4

• ASCA is a serological antibody marker with no role in lymphoma diagnosis or management

Clinical Implications

• Do not order ASCA testing for DLBCL evaluation - it has no diagnostic, prognostic, or therapeutic relevance in this malignancy 4

• If ASCA antibodies are incidentally positive in a DLBCL patient, consider evaluating for concurrent inflammatory bowel disease or autoimmune conditions 5, 2, 1

• Focus on established DLBCL markers including IPI score, molecular subtyping (MYC/BCL2 rearrangements), and PET/CT staging instead 4